Peginesatide
drugOn this page
Also known as AF-37702AF37702HematidePeginesatida
Summary
Peginesatide (CHEMBL2107866) is an approved protein (ATC B03XA04) targeting EPOR; indicated across 1 condition including anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: B03XA04
- Targets: 1 (EPOR)
- Indications: 1 condition
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107866 |
| Name | Peginesatide |
| Type | Protein |
| Max phase | 4 |
| ATC | B03XA04 |
Also known as: AF-37702, AF37702, Hematide, Peginesatida, Peginesatide, PEGINESATIDE
Parent form; salt/anhydrous children: CHEMBL1963684
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| EPOR | Eythropoietin receptor | Agonist | 10.43 | 0.9% | P19235 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): EPOR.
Top Reactome pathways
5 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signaling by Erythropoietin | 1 | EPOR |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 1 | EPOR |
| Erythropoietin activates Phospholipase C gamma (PLCG) | 1 | EPOR |
| Erythropoietin activates STAT5 | 1 | EPOR |
| Erythropoietin activates RAS | 1 | EPOR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 1 |
| brain development | 1 |
| heart development | 1 |
| erythropoietin-mediated signaling pathway | 1 |
| decidualization | 1 |
| cytokine-mediated signaling pathway | 1 |
| proteasome-mediated ubiquitin-dependent protein catabolic process | 1 |
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 3 | MONDO:0002280 | EFO:0004272 |
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE3 | 5 |
| PHASE1 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01737879 | PHASE4 | TERMINATED | Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis |
| NCT00597584 | PHASE3 | COMPLETED | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis |
| NCT00597753 | PHASE3 | COMPLETED | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis |
| NCT00598273 | PHASE3 | COMPLETED | Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis |
| NCT00598442 | PHASE3 | COMPLETED | Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis |
| NCT01478971 | PHASE3 | COMPLETED | Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis |
| NCT00109291 | PHASE2 | TERMINATED | Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease |
| NCT00228436 | PHASE2 | COMPLETED | Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients |
| NCT00228449 | PHASE2 | COMPLETED | Peginesatide for Anemia in Chronic Hemodialysis Patients |
| NCT00272662 | PHASE2 | COMPLETED | Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy |
| NCT00314795 | PHASE2 | COMPLETED | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease |
| NCT00372489 | PHASE2 | TERMINATED | Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD |
| NCT00434330 | PHASE2 | COMPLETED | Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis |
| NCT00453973 | PHASE2 | TERMINATED | Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU) |
| NCT00680043 | PHASE2 | COMPLETED | Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA |
| NCT00752609 | PHASE2 | COMPLETED | Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa. |
| NCT00752791 | PHASE2 | COMPLETED | Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin. |
| NCT00097747 | PHASE1 | COMPLETED | Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers |
| NCT00629876 | PHASE1 | TERMINATED | A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).